CA2534271A1 - A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss - Google Patents

A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss Download PDF

Info

Publication number
CA2534271A1
CA2534271A1 CA002534271A CA2534271A CA2534271A1 CA 2534271 A1 CA2534271 A1 CA 2534271A1 CA 002534271 A CA002534271 A CA 002534271A CA 2534271 A CA2534271 A CA 2534271A CA 2534271 A1 CA2534271 A1 CA 2534271A1
Authority
CA
Canada
Prior art keywords
obesity
treatment
facilitate
pharmaceutical composition
weight loss
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002534271A
Other languages
English (en)
French (fr)
Inventor
Jotham Wadsworth Coe
Brian Thomas O'neill
Steven Bradley Sands
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2534271A1 publication Critical patent/CA2534271A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002534271A 2003-08-22 2004-08-09 A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss Abandoned CA2534271A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49735303P 2003-08-22 2003-08-22
US60/497,353 2003-08-22
PCT/IB2004/002604 WO2005018622A1 (en) 2003-08-22 2004-08-09 A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss

Publications (1)

Publication Number Publication Date
CA2534271A1 true CA2534271A1 (en) 2005-03-03

Family

ID=34216115

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002534271A Abandoned CA2534271A1 (en) 2003-08-22 2004-08-09 A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss

Country Status (7)

Country Link
US (1) US20050043406A1 (enExample)
EP (1) EP1658059A1 (enExample)
JP (1) JP2007503384A (enExample)
BR (1) BRPI0413670A (enExample)
CA (1) CA2534271A1 (enExample)
MX (1) MXPA06002049A (enExample)
WO (1) WO2005018622A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000806A2 (en) * 2003-06-10 2005-01-06 Georgetown University Ligands for nicotinic acetylcholine receptors, and methods of making and using them
EP1670452A2 (en) * 2003-09-25 2006-06-21 Warner-Lambert Company LLC Method of use of aminoacids having affinity for the a2d protein
KR100768974B1 (ko) * 2003-09-25 2007-10-22 워너-램버트 캄파니 엘엘씨 알파2델타-단백질에 대한 친화성을 갖는 아미노산
WO2007115092A2 (en) * 2006-03-29 2007-10-11 Georgetown University 10-substituted cytisine derivatives and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200001840T2 (tr) * 1997-12-31 2000-12-21 Pfizer Products Inc. Arile bağlı azopolisiklik bileşikler
AU3735000A (en) * 1999-05-05 2000-11-21 Warner-Lambert Company Modulation of substance p by gaba analogs and methods relating thereto
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US20020010192A1 (en) * 2000-06-02 2002-01-24 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands

Also Published As

Publication number Publication date
MXPA06002049A (es) 2006-05-19
BRPI0413670A (pt) 2006-10-24
JP2007503384A (ja) 2007-02-22
US20050043406A1 (en) 2005-02-24
WO2005018622A1 (en) 2005-03-03
EP1658059A1 (en) 2006-05-24
WO2005018622A8 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
CA2384111A1 (en) Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
AU7109000A (en) Dibenzopyrans as glucocorticoid receptor antagonists for treatment of diabetes
CA2392096A1 (en) Polymorphic form of atorvastatin calcium
CA2368775A1 (en) Treatment of cardiovascular and related pathologies
HUP0003386A3 (en) Use of crf antagonists for the preparation of pharmaceutical compositions treating depression, cardiovascular diseases
NO20020770L (no) Anvendelse av monoaminoksidaseinhibitorer for fremstilling av legemidler egnet for behandling av obesitas
CA2392028A1 (en) Carbamate derivatives having muscarinic receptor antagonist activity
IL139227A0 (en) N-substituted aminotetralins as ligands for the neuropeptide yy5 receptor useful in the treatment of obesity and other disorders
CA2281844A1 (en) Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
WO2003024928A3 (en) Novel aminoazetidine, -pyrrolidine and -piperidine derivatives
HUP0200881A2 (en) Renin inhibitors, process for preparation of the compounds, pharmaceutical compositions containing them and their use
HK1046405A1 (zh) 作为nmda受体拮抗剂用於治疗疼痛的取代的1，5-二氢吡咯-2-酮衍生物
WO2006066173A3 (en) Novel mch receptor antagonists
IL137365A0 (en) Heteroaryl-substituted pyrrole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HUP0203976A3 (en) Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
EP1159970A3 (en) A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss, comprising a nicotine receptor partial agonist and an anti-obesity agent
CA2534271A1 (en) A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
HUP0201710A3 (en) Biphenyl derivatives as antagonists of the neurokinine-1 receptor, process for producing them and pharmaceutical compositions containing them
IL145645A0 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
WO2004098641A3 (en) A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
PL373192A1 (en) Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
WO2004093789A3 (en) Use of galr3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
WO2003076426A3 (en) Pyridinyloxy derivatives as 5-ht receptor ligands
AU2002315485A1 (en) Compositions and methods for the treatment of body weight disorders, including obesity
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued